Lilly's Weight Loss Pill Receives Approval in the UK

GOOGL has lost 6.4% in the last 24 hours, with RSI at 38.3, indicating weak momentum. MACD is below the signal line and negative, suggesting bearish short-term momentum. The price is below both the SMA20 and SMA50, which paints a negative technical outlook. Although the news headline is not directly related to GOOGL, a decline in overall market risk appetite could impact the stock. In the short term, the downtrend is likely to persist, but as the stock approaches oversold territory, bargain buying may emerge.

The news of Lilly's weight-loss drug receiving approval in the UK is viewed as a positive catalyst for the company and could provide short-term support to the stock. However, technical indicators show the RSI at 72, indicating overbought conditions, which may limit the pace of the rally and could lead to short-term consolidation. The MACD remains above its signal line, and the price is trading above the 20-day and 50-day moving averages, suggesting a strong overall trend. Nevertheless, the sharp 9% rise over the last 24 hours could trigger profit-taking, warranting caution. Therefore, while the bias remains upward, given the overbought signals, a limited upside or sideways movement is more likely than a strong continuation.